MIRA Pharmaceuticals (MIRA) Stock Price, News & Analysis

Company Overview

MIRA Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on developing novel treatments for neurological and neuropsychiatric disorders. The company’s research is directed toward therapies for conditions with significant unmet medical needs, including anxiety, depression and chronic pain.

MIRA’s lead product candidate, MIRA-55, is an oral ketamine analog being developed for potential use in anxiety, depression and neuropathic pain. The company is evaluating the compound’s therapeutic potential and safety as it advances its development program.

MIRA Pharmaceuticals is headquartered in the United States and is led by Chief Executive Officer Erez Aminov. As an early-stage drug developer, the company’s operations are primarily focused on pharmaceutical research, clinical development and pursuing regulatory pathways for its pipeline candidates.

Key Stats

• Today's Range: $0.86 to $0.90
• 50-Day Range: $0.61 to $0.93
• 52-Week Range: $0.60 to $2.45
• Volume: 61,367 shs
• Average Volume: 1.66 million shs
• Market Capitalization: $36.62 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.50
• Consensus Rating: Hold

MIRA Pharmaceuticals Stock Analysis - MarketRank™

MIRA Pharmaceuticals scored higher than 49% of companies evaluated by MarketBeat, and ranked 556th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Hold

Consensus Rating

MIRA Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

MIRA Pharmaceuticals has a consensus price target of $3.50, representing about 301.6% upside from its current price of $0.87.

Amount of Analyst Coverage

MIRA Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of MIRA Pharmaceuticals is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of MIRA Pharmaceuticals is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

MIRA Pharmaceuticals has a P/B Ratio of 3.49. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.33% of the float of MIRA Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

MIRA Pharmaceuticals has a short interest ratio ("days to cover") of 0.14, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in MIRA Pharmaceuticals has recently increased by 118.14%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

MIRA Pharmaceuticals does not currently pay a dividend.

Dividend Growth

MIRA Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.59

News Sentiment

MIRA Pharmaceuticals has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for MIRA Pharmaceuticals this week, compared to 1 article on an average week.

Search Interest

2 people have searched for MIRA on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, MIRA Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

19.89% of the stock of MIRA Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

35.16% of the stock of MIRA Pharmaceuticals is held by institutions.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 9/29/2026
• Next Earnings (Estimated): 12/02/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:MIRA
• Previous Symbol: NASDAQ:MIRA
• CIK: 1904286
• Web: mirapharmaceuticals.com
• Phone: (813) 369-5150
• Fax: N/A
• Employees: 2
• Year Founded: 1978

Price Target and Rating

• Average Price Target for MIRA Pharmaceuticals: $3.50
• High Price Target: $3.50
• Low Price Target: $3.50
• Potential Upside/Downside: +301.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.24)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$10.44 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -106.95%
• Return on Assets: -104.18%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 200.08
• Quick Ratio: 200.08

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.25 per share
• Price / Book: 3.49

Miscellaneous

• Outstanding Shares: 42,020,000
• Free Float: 33,664,000
• Market Cap: $36.62 million
• Optionable: Not Optionable
• Beta: 1.52